Gedea Biotech is focused on developing pHyph, an innovative vaginal tablet designed to treat and prevent bacterial vaginosis (BV) without the use of antibiotics. This product aims to address a significant medical need, as BV is a common and recurring issue affecting millions of women globally. Clinical trials have demonstrated that pHyph not only achieves a cure rate comparable to traditional antibiotics but also boasts a superior safety profile, significantly reducing the risk of secondary infections and recurrence. The mechanism of action for pHyph involves restoring the vaginal microbiome and normalizing pH levels, which helps create an environment conducive to healthy bacterial growth while breaking down biofilms that harbor infectious bacteria.

In addition to its primary focus on bacterial vaginosis, Gedea Biotech is also exploring the efficacy of pHyph in treating vaginal yeast infections. The company has initiated clinical studies to confirm the safety and effectiveness of pHyph for this indication, with promising preliminary results. By providing a dual-action treatment for both BV and yeast infections, Gedea Biotech aims to offer a comprehensive solution that minimizes the reliance on antibiotics, thereby addressing concerns related to antimicrobial resistance. The company is actively pursuing regulatory approvals in Europe and the United States, with the goal of making pHyph available to women in need of effective and safe treatment options.

Sweden

Gedea Biotech develops pHyph to treat and prevent recurrence of bacterial vaginosis. Bacterial vaginosis (BV) is a very common condition with a prevalence of 10-30% for women of childbearing age. The symptoms can be very disturbing and include an often profuse thin, white, “fishy” smelling vaginal discharge. Standard treatment consists of antimicrobials, but recurrence rate is 15–30 % within 3 months. pHyph will treat the infection and prevent recurrence without the use of antmicrobials. Antimicrobial resistance is one of the World Health Organisation’s top ten threats to global health 
and research into novel non-antimicrobial based treatments is timely. 

Gedea Biotech

Company Details